Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a transformative therapy for type 2 diabetes (T2D) and obesity. Developed by Novo Nordisk and approved by regulatory bodies worldwide since 2017, it represents a significant advancement in metabolic disease management.

Mechanism of Action

Semaglutide mimics the endogenous hormone GLP-1, which:

1. Stimulates insulin secretion from pancreatic β-cells in a glucose-dependent manner.

2. Suppresses glucagon release, reducing hepatic glucose production.

3. Slows gastric emptying, promoting satiety and reducing caloric intake.

4. Acts on hypothalamic appetite centers to decrease hunger.

Its extended half-life (∼1 week) is achieved through structural modifications, including albumin binding, allowing once-weekly dosing.

Clinical Applications

1. Type 2 Diabetes (Brands: Ozempic®, Rybelsus®)

• Glycemic control: Reduces HbA1c by 1.5–2.0% as monotherapy or with other agents.

• Cardiovascular benefits: Demonstrated 26% reduction in major adverse cardiovascular events (SUSTAIN-6 trial).

• Weight loss: Patients lose 4–6% of body weight on average.

2. Obesity (Brand: Wegovy®)

• STEP trials: Participants achieved average weight loss of 14.9–17.4% at 68 weeks.

• Mechanism: Targets both physiological (hormonal) and behavioral (appetite) pathways of weight regulation.

3. Emerging Indications

• NASH (Non-alcoholic steatohepatitis): Reduces liver fat and inflammation.

• Heart failure: Improves outcomes in preserved ejection fraction (HFpEF).

• Polycystic ovary syndrome (PCOS): Under investigation for metabolic benefits.

Administration and Formulations

Safety and Tolerability

Common side effects (mostly transient):

• Gastrointestinal: Nausea (15–20%), vomiting, diarrhea (manageable via dose titration).

• Rare risks: Acute pancreatitis (0.1–0.3%), gallbladder disease, diabetic retinopathy (in T2D patients with pre-existing history).
  Contraindications: Medullary thyroid cancer (boxed warning), pregnancy, severe GI disease.

Market Impact and Accessibility

• Global adoption: >1.5 million users for obesity alone (2023).

• Cost challenges: List price of ∼$1,300/month in the U.S.; insurance coverage remains inconsistent.

• Supply constraints: High demand led to intermittent shortages (2022–2024).

Future Directions

1. Combination therapies: With amylin analogues (e.g., cagrilintide) for synergistic weight loss.

2. Cardio-metabolic protection: Potential to reduce atherosclerosis progression.

3. Neuroprotective roles: Preclinical data suggest benefits in Alzheimer’s and Parkinson’s.

Conclusion
Semaglutide has redefined standards for treating metabolic disorders, offering unprecedented efficacy in weight reduction and glycemic control. While challenges in cost and access persist, its expanding therapeutic potential positions it as a cornerstone of 21st-century medicine. Ongoing research promises to unlock further applications, solidifying its role beyond diabetes and obesity.